Dr. Chul Ha is professor and chairman of the department of radiation oncology at UT Health San Antonio and the Cancer Therapy & Research Center.
He is a nationally recognized expert in radiation oncology, especially for hematological malignancies such as lymphoma, myeloma and leukemia. He has a special expertise in unique treatment procedures such as total body irradiation in preparation for bone marrow transplant, total skin electron beam radiation therapy for certain skin conditions and radioimmunotherapy for lymphomas. His current research interests include the development of drugs that reduce the side effects of radiation therapy and chemotherapy, and the development of agents that are selective to cancer cells for imaging and targeted therapy.
He completed his medical education and residency training at Harvard University and spent 14 years at The University of Texas M.D. Anderson Cancer Center before joining the faculty at the UT Health Science Center.
Ganapathy, S., Xiao, S., Seo, S. J., Lall, R., Yang, M., Xu, T., Su, H., Shadfan, M., Ha, C. S. & Yuan, Z. M. Low-dose arsenic induces chemotherapy protection via p53/NF-kappaB-mediated metabolic regulation. Oncogene doi: 10.1038/onc.2013.81(2013). PMID: 23524579
Su, H., Ganapathy, S., Li, X., Yuan, Z. M. & Ha, C. S. p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan. Int. J. Radiat. Oncol. Biol. Phys. 1;92(5):1116-22 (2015). PMID: 26025778; PMCID: PMC4509863
Swanson, G. P., Jones, W. E.,3rd, Ha, C. S., Jenkins, C. A., Kumar, A. P. & Basler, J. Tolerance of Phellodendron amurense Bark Extract (Nexrutine(R)) in Patients with Human Prostate Cancer. Phytother. Res. 29(1):40-2 (2014). PMID: 25205619; PMCID: PMC4507270